Oxford Nanopore Technologies plc is a British biotechnology company specialising in DNA and RNA sequencing. Based in Oxford, it develops and markets instruments, consumables and software built around a single approach: measuring changes in an electrical current as a molecule passes through a nanoscale pore. Its website, nanoporetech.com, presents its platforms and their scientific applications.
A technology rooted in research at Oxford
Founded in 2005, the company draws in particular on the work of Hagan Bayley at the University of Oxford. Its aim is to turn nanopores into tools for reading biological molecules, using an architecture that differs from sequencing methods based on DNA synthesis and optical detection.
A major milestone came in 2014, when the first users gained access to MinION, a sequencer compact enough to be taken outside a centralised laboratory. Oxford Nanopore subsequently expanded its range to meet the need for greater throughput and automation. Its listing on the London Stock Exchange in 2021 marked a new phase in its industrial and commercial development.
Reading genomes, from the field to the laboratory
Oxford Nanopore’s technology enables long DNA fragments to be sequenced and data to be generated as the analysis progresses. This real-time reading can help users adjust their experiments without waiting for an entire run to finish. It also enables direct RNA analysis and the detection of certain chemical modifications to bases, which are particularly useful for studying gene regulation.
The portfolio includes MinION, GridION and PromethION systems. These platforms cover uses ranging from targeted experiments to projects requiring greater capacity. The offering combines devices, sequencing flow cells, sample preparation kits and software tools that convert the electrical signal into usable sequences.
Applications include basic research, the study of structural variations in genomes, microbiology, pathogen surveillance and plant breeding. The portability of some equipment facilitates fieldwork, without eliminating the constraints of sample preparation, quality control and bioinformatics analysis. Performance also depends on the protocols, consumables and software versions used.
What next?
For Oxford Nanopore, the challenge is to translate the possibilities of its technology into routine, reproducible uses. This involves improving accuracy, simplifying workflows and integrating with laboratory infrastructure. The development of clinical applications also requires appropriate validation and compliance with the regulatory frameworks specific to each market.
In competing with other sequencing platforms, the company is banking on long reads, native molecule analysis and the progressive availability of results. Its trajectory will depend on its ability to demonstrate the practical and economic value of these features while supporting users with very different needs.